N-Glycosylation-defective receptor for erythropoietin can transduce the ligand-induced cell proliferation signal  by Nagao, Masaya et al.
FEBS 16118 FEBS Letters 373 (1995) 225-228 
,¥-Glycosylation-defective receptor for erythropoietin can transduce the 
ligand-induced cell proliferation signal 
Masaya Nagao, Emi Morishita, Yasumitsu Hanai, Kazuhira Kobayashi, Ryuzo Sasaki* 
Department of Food Science and Technology, Facul(v of Agricuhure, Kvoto University, Kyoto 606-01, Japan 
Received 22 August 1995 
Abstract Erythropoietin receptor (EPOR) contains a single N- 
linked sugar in an extracellular domain. It has been suggested 
that an erythroleukemia cell line with high sensitivity to EPO 
e,~presses a high molecular mass form of EPOR, which appears 
to be a highly N-glycosylated form responsible for EPO-mediated 
signal transduction [Sawyer and Hankins (1993) Proc. Natl. 
Acad. Sci. USA 90, 6849--6853]. To examine the role of the 
N-linked sugar chain, we prepared EPO-dependent cell lines ex- 
pressing the wild-type EPOR and N-glycosylation-defective 
EPOR. There was little difference in the expression of EPOR on 
lhe cell surface, EPO binding kinetics, and EPO-indnced cell 
proliferation between the clones expressing the mutant EPOR 
and those expressing the wild-type EPOR. 
,~.2ey words: Erythropoietin receptor; N-Glycosylation; 
gignal transduction 
,. Introduction 
Carbohydrates attached to proteins have been shown to play 
• role in multiple biochemical pathways including folding, sta- 
bility, targeting and clearance of proteins, and cell recognition 
~see [1] for review). Most of the growth factor receptors are 
:Aycoproteins and the functions of the carbohydrates have been 
, xamined using several receptors [~15], In some receptors the 
, arbohydrates have been implicated in ligand binding and the 
• ignal transduction pathway. Acquisition of the ligand-binding 
. apacity by the epidermal growth factor receptor is glycosyla- 
ion-dependent [6,7]. N-Glycosylation at a specific site of the 
nsulin receptor fl subunit appears to be important for the 
eceptor activation and transmembrane signaling [4,5]. Degly- 
:osylation of the basic fibroblast growth factor receptor results 
n the loss of the ligand-binding [8] and sialylation of the N- 
inked sugars in the somatostatin receptor is required for main- 
enance of the high-affinity binding state [9]. 
EPO transduces the proliferation and differentiation signal 
hrough its receptor on erythroid precursor cells and some 
)ther lineage cells [16,17]. By molecular cloning of murine 
18,19] and human [20,21] EPOR, the mature 53-kDa EPOR 
ms been predicted to consist of an extracellular 225-226 amino 
lcid domain, 22 amino acid transmembrane r gion, and an 
ntracellular 236 amino acid domain. A single N-glycosylation 
;ite is present in the extracellular domain in EPOR. Studies on 
"Corresponding author. Fax: (81) (75) 753-6274. 
4bbreviations: EPO, erythropoietin; EPOR, erythropoietin receptor; 
BHK, baby hamster kidney; IL-3, interleukin 3; MTT, 3-(4,5-dimethyl- 
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide. 
the IL-3-dependent Ba/F3 cells that were stably transfected 
with the wild-type EPOR and became EPO-responsive indi- 
cated that the EPOR with 66 kDa was the mature glycosylated 
form exposed on the cell surface [22] and that the 72-kDa 
EPOR could be an EPO-induced phosphorylated form of 66- 
kDa EPOR [23,24]. BHK cells stably transfected with the wild- 
type EPOR cDNA and the N-glycosylation-defective mutant 
expressed 68-kDa and 66-kDa EPOR, respectively and the two 
forms of EPOR were not different in the ligand-binding assay 
[14]. More recently, Sawyer and Hankins [25] reported that an 
EPO-dependent murine erythroleukemia cell line, which was 
highly sensitive to EPO, expressed the 78-kDa high molecular 
mass form of EPOR and that the 78-kDa EPOR was a func- 
tional form of EPOR because it was correlated well with cell 
surface xpression, endocytosis and EPO-induced phosphoryl- 
ation. They also indicated that the 78-kDa EPOR resulted from 
high N-glycosylation rather than phosphorylation, suggesting 
the importance of N-glycosylation for expression of the func- 
tional EPOR or the ligand-sensitive EPOR. These findings of 
EPOR prompted us to examine the role of the receptor glyco- 
sylation using the N-glycosylation-defective EPOR. Herein, we 
prepared EPO-dependent cell lines expressing wild-type or mu- 
tant EPOR, and compared the ligand-saturation curves with 
respect o EPO binding and EPO-dependent cell proliferation. 
2. Materials and methods 
2. I. EPO-dependent cells expressing mouse wild-o,pe EPOR and N- 
glveosylation-defective EPOR 
The plasmid for expression of N-glycosylation-defective EPOR 
(Asn~Gln) was prepared [14] from the plasmid for expression of 
wild-type EPOR (pXM 190) [18]. IL-3-dependent BaF-BO3 cells, a sub- 
clone of the mouse pro-B cell line (Ba/F3), were maintained in the 
medium consisting of RPMI1640, 10% fetal calf serum and 10% 
WEHI3B conditioned medium as a source of IL-3. To prepare BaF- 
BO3 cells expressing EPOR, 7 x 107 cells in 0.8 ml of RPMI1640 were 
co-transfected with 10/lg pKSVl0neo and 100/lg of the wild-type or 
N-glycosylation-defective EPOR by electroporation. The transfected 
cells were cultured in a 96-well plate in the complete medium plus 
1 mg/ml G418. Drug-resistant colonies were picked up and the resistant 
cells were cloned by limiting dilution. The cloned cells were examined 
specific binding with the radioiodinated EPO and finally we established 
four cells lines expressing wild-type EPOR and lwo cell lines expressing 
N-glycosylation-defective EPOR. They were maintained in the medium 
containing the WEHI3B conditioned medium. 
2.2. Western blotting of EPOR expressed in BaF-B03 
BaF-BO3 cells expressing EPOR were solubilized with 100 HI of 1% 
Triton X-100 and the solubilized EPOR was affinity purified by an 
EPO-conjugated Sepharose gel column [26]. After subjected to SDS- 
polyacrylamide g l electrophoresis, EPOR was detected with anti- 
EPOR N-terminal sequence antiserum using a peroxidase-labeled anti- 
rabbit IgG and ECL kit (Amersham) [26]. 
2.3. EPO dependency ofcell proliferation 
For the assay of EPO dependency ofcell proliferation, the cells were 
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washed extensively with RPMI 1640 before assay. Cells at a density of 
30,000/well were seeded in 96-well microtiter plates in the presence of
various concentrations of EPO and cultured for 40 h. Viable cells were 
measured colorimetrically b the use of the cleavage of MTT [27]. 
2.4. EPO binding 
Recombinant human EPO [28,29] was radioiodinated ata specific 
activity of I. 11 MBq//ag protein [30]. Binding of EPO was assayed as 
described previously [19] except that incubations for binding were done 
at 4°C for 30 min using 2 x 10 6 cells. Specific binding was defined as 
the difference inbound radioactivity between samples incubated inthe 
absence and the presence of 100-fold unlabeled EPO. 
3. Results and discussion 
We established four BaF-BO3 cell lines expressing wild-type 
EPOR, termed ER 14, and two cell lines expressing N-glycosyl- 
ation-defective EPOR, termed ERM1 and -2. Parental BaF- 
BO3 cells required IL-3 for their survival and proliferation, 
whereas all of these colonies expressing EPOR could proliferate 
in the presence of EPO instead of IL-3 as shown later. However, 
these clones were never maintained with EPO because culture 
with EPO might result in commitment toerythroid cells and in 
expression of the endogenous EPOR [31]. First, we analyzed 
EPOR by Western blotting (Fig. 1). EPOR was undetectable 
in the parental BaF-BO3 cells, while all of the EPOR-trans- 
fected cells lines expressed EPOR. The molecular sizes of 66 
kDa for the wild-type EPOR and 62 kDa for the N-glycosyla- 
tion-defective EPOR were consistent with those of EPOR with 
and without N-linked sugar, respectively [14]. 
Next, the binding properties of EPO were examined using 
radioiodinated recombinant EPO. There was no specific bind- 
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Fig. 1. Western blot analysis of EPOR. B = parental BaF-BO3 cells; 
ERI~, = clones expressing the wild-type EPOR; ERM 1 and 2 = clones 
expressing the N-glycosylation-defective EPOR. In all cases, l 0  7 cells 
were used except that 3 × 10 7 cells were used for ER3. Solubilization 
and purification of EPOR were as described insection 2. Proteins were 
fractionated with 6% SDS-polyacrylamide g l electrophoresis and 
EPOR was detected. +CHO and -CHO indicate EPOR with and with- 
out N-linked sugar, respectively. 
ing of EPO on the parental BaF-BO3 cells and the specific 
binding of the cells expressing EPOR was completely abrogated 
when the radioactive EPO was preincubated with excess olu- 
ble-EPOR [26] capable of binding with the ligand (data not 
shown). As Fig. 2 shows, the Scatchard plots of ligand satura- 
tion curves of all BaF-BO3 clones expressing EPOR are 
straight lines, indicating that they have a single affinity for 
EPO. Dissociation constants were 530, 470, 430, and 560 pM 
for four clones (ERI-4) expressing wild-type EPOR, respec- 
tively (Fig. 2A), and those for two clones (ERM1 and -2) ex- 
pressing the mutant EPOR were 690 pM (Fig. 2B); there was 
not much difference in the dissociation constant of the two 
types of EPOR. The total numbers of the wild-type EPOR 
(ERIM) were 2700, 440, 3200, and 3000 sites/cell and those of 
the mutant EPOR (ERM1 and -2) were 340 and 1700. This 
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Fig. 2. Scatchard plots of EPO binding. (A) Clones expressing the wild-type EPOR. (o) ER1, (©) ER2, (A) ER3, (u) ER4. (B) Clones expressing the 
N-glycosylation-defective EPOR. (©) ERM1, (o) ERM2. Each point indicates the average of triplicate assays. 
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l ig. 3. EPO-dependent proliferation. (A) Clones expressing the N-glycosylation-defective EPOR. • = ERM1, • = ERM2, © = parental cells. 
(t3) Clones expressing the wild-type EPOR. • = ER1, • -- ER2, • = ER3, © = parental cells. Each point is the average of triplicate assays. 
i adicates that N-glycosylation is not essential for EPOR to be 
~ransported onto the cell surface but N-glycosylation appears 
~o somewhat facilitate the transport because the wild-type 
F :,POR is usually expressed more abundantly on the cell surface 
i han the mutant counterpart. This tendency was also observed 
when the wild-type and N-glycosylation-defective EPOR were 
~xpressed in BHK cells [14]. 
We next examined whether the N-glycosylation-defective 
EPOR could transduce the EPO signal for cell proliferation or 
~ot. As Fig. 3 shows, parental BaF-BO3 did not respond to 
EPO. The BaF-BO3 clones expressing the mutant EPOR (Fig. 
;A) proliferated in the presence of EPO with a dose-response 
dmilar to the clones expressing the wild-type EPOR (Fig. 3B). 
In conclusion, N-glycosylation of EPOR is not essential for 
ts expression on the cell surface nor for the ligand binding, 
vhich is consistent with our previous findings obtained using 
EPO-independent BHK cells [14] and those obtained from the 
reatment of EPO-responsive cells with glycosylation i hibitors 
15]. The N-glycosylation-defective EPOR can transduce EPO- 
mduced cell proliferation signal and N-glycosylation of EPOR 
loes not facilitate the signal transduction. Thus the high re- 
,ponse of 78 kDa EPOR to EPO found by Sawyer and Hanks 
25] on erythroleukemia cells would not be due to N-glycosyla- 
ion but might be due to other modifications which deserve 
"urther analyses to elucidate the molecular mechanism of EPO- 
nduced signal transduction. 
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